<div>My daughter Lucy absolutely loves the water – whether it’s a warm bath or a refreshing pool, that girl will stay in and “SPLASH SPLASH SPLASH” with her sisters and dad forever. On a recent family vacation, she got a little cold, but I knew something was up because she wasn’t interested in the pool and seemed especially tired, fussy, and floppy. And when we came home, things got worse. Our normal routine on school days was to lay her next to her sleeping 7-year old sister – her cute babbles were the only way to get her night owl big sis to wake up in a good mood before school. However, over the next few days, she wasn’t babbling much at all and her older sister complained, “I can’t get Goose to smile at all this morning.” We soon met with the neurologists at Stanford’s Lucille Packard Children’s Hospital, who were also concerned. They conducted an extensive workup including a brain MRI, EEG (for seizures), spinal taps (for infections and neurotransmitter problems), and EMG / nerve conduction studies, all of which were reassuring and couldn’t explain why she was seemingly so off her baseline. After about a week, however, the symptoms mostly went away and she returned to her babbling and smiley self, albeit a bit less strong than before. To be thorough, though, broad genetic testing was sent off.
</div>
<div> 
</div>
<div>One month later, we received the text no parent ever wants to get: “Lucy’s genetic tests are back and I’m concerned. Let’s meet in an hour.” No surprise, I spent that hour in the bathtub splashing with Lucy, trying to distract us all in her happy place. Then came the shocking news that Lucy has two bad copies of her PGAP3 gene, one of the many genes involved in sticking important molecules to cells and in cell communication. She has one tiny amino acid difference in one tiny protein – yet, it’s an essential one. And when she’s sick, even with a common cold, her cells work and communicate even less effectively. Her diagnosis is extremely rare, with only a handful of other patients known worldwide. We weren’t the only ones shocked; her pediatric neurologist also never suspected, given Lucy's overall mild symptoms, that she would be delivering such a devastating diagnosis. Most kids with PGAP3-CDG are markedly disabled and develop very severe symptoms in early childhood years. At 11 months, Lucy sits, babbles, plays, and is working toward her first steps. We were told that there is currently no cure and no treatment, and that she will likely suffer from low muscle tone and ataxia, have moderate to severe intellectual disability, develop autistic features, never develop expressive speech, and may develop intractable seizures. We looked through tears at our smiling, curious baby and defiantly didn’t believe it.
</div>
<div> 
</div>
<div>Unfortunately, the genetic diagnosis is true. Equally unfortunately, given that so few people have this genetic disorder, there are no trials anywhere in the world for PGAP3 and there is no active research on developing a therapy for children with PGAP3. However, we are still defiant, and there is good reason to believe there is a lot of hope for Lucy. One of her copies of PGAP3 is a new variant, which may be slightly milder than cases described previously. Few children with this disorder have ever been diagnosed so young or had such a mild initial presentation. Most importantly, our neurogeneticist at Stanford has connected us with Dr. Ethan Perlstein, a Harvard trained PhD scientist, and Perlara, his biotechnology company based in the Bay Area, that exclusively works directly with families whose children have genetic disorders similar to Lucy's (“congenital disorders of glycosylation”). Since 2014, Dr. Perlstein’s research teams have worked to identify potential cures for these single gene mutations. For instance, Perlara worked with the family of Maggie, a child who has a genetic condition very similar to Lucy's. In 2019, the team developed the scientific models of her gene first with yeast, then more advanced models, to test existing medications that might be re-purposed to make her faulty protein more functional. A rarely used, but safe, Japanese nerve pain medication was found to boost the necessary protein by 400%, which was sufficient to reverse many aspects of the disease. The drug was given to Maggie, and the results were astounding. Two others with the disease also had similar results. The medicine is now FDA approved for a phase 3 trial at Mayo Clinic for dozens of children with her disorder.
</div>
<div> 
</div>
<div>Using these exact same models already created, the researchers can relatively simply switch Maggie’s gene with Lucy’s gene to identify an effective therapy and potentially a cure. Lucy is young, and as my grandfather would say, there is light behind those eyes – she is curious, loving, chatty, and has not yet developed any of the more serious features of this syndrome. She is truly an N-of-1, with a novel variant and a novel set of life circumstances. No child in the world with her condition has had the opportunity to have an effective treatment so early in life, which means that the sky is the limit to what we can do for her.
</div>
<div> 
</div>
<div>Unfortunately, because there are simply not enough kids known to have Lucy’s genetic disorder, no pharma company, government, or investor is interested in funding this research – it has to be us. In order to accomplish this, the research team needs about one year of full-time to work to build Lucy’s gene into yeast, worm, and fly models, test nearly 6,000 compounds to determine which boost her protein’s expression or function, and then ensure that compound does the same thing in Lucy’s own fibroblast (immune) cells, using the same playbook as the identification of Maggie’s drug above.
</div>
<div> 
</div>
<div>As I write this, Lucy is playing on her mat with her two big sisters, cracking up as she accidently squirts her sister with one of her bath toys still filled with water. And yet I remember those few days she made less eye contact, fell over easily, and stopped babbling just because she had a little cold, and I feel the floor drop out from under me - the thought of losing Lucy, this little person she has already become, is inconceivable. With your help, we can start the work nearly immediately and realistically find and begin a treatment by her second birthday, before any of the more severe symptoms are expected to develop. Lucy will be the N-of-1, but the work done for her treatment will hopefully lead to treatments for the dozens of children suffering from this condition around the world. Please help us fund this research and give Lucy the gifts of speech, walking, and a life without seizures.
</div>
<div> 
</div>
<div> 
</div>
<div> 
</div>
<div>If you're interested in the actual science, this very accessible presentation by Dr. Perlstein details both the peer-reviewed scientific and real-life N of 1 progress that has been made with older children who have an upstream genetic disorder on the same pathway as Lucy's. This work came from this exact same type of N of 1 research. Now all we have to do is plug Lucy's gene into this research model and find her a cure: <a href="https://www.youtube.com/watch?v=bXcgWLqhmgE" target="_blank" class="" rel="nofollow noopener noreferrer">https://www.youtube.com/watch?v=bXcgWLqhmgE</a>
</div>
<div><br />
</div>
<div>——————-
</div>
<div>Update May 9, 2022 - Thanks to the incredible initial outpouring of support that we received, we were able to set off on the first experiments (2-3 months / ~50K). As of 8:30am this morning, the research protocols to create “Lucy PGAP3 yeast” and “Lucy PGAP3 worm” avatars are all set and the bench research is scheduled to begin within days! Follow Lucy’s journey here: <a href="https://www.instagram.com/lucythepgap3goose/" target="_blank" class="" rel="nofollow noopener noreferrer">https://www.instagram.com/lucythepgap3goose/</a>
</div>
<div><br />
</div>
<div>----------------
</div>
<div>Update June 15, 2022: In addition to the drug repurposing campaign described above, which is possible thanks to the generosity of everyone who has donated here, we are also pursuing development of gene therapy for Lucy and other PGAP3 patients with the incredible research team at Nationwide Children's Hospital.  We are very excited to announce that we have set up a 501(c)(3) non-profit, "Moonshots for Unicorns," to raise the funds required for this astronomical effort.  For 100% tax deductible donations, you can now donate directly at: <a href="https://moonshotsforunicorns.org/." target="_blank" class="" rel="nofollow noopener noreferrer">https://moonshotsforunicorns.org/.</a> Thank you so much for your continued generosity!
</div>

Firoozeh Ettehad

Anonymous

Jean Lee

Wilhelm Leinemann

Laura Roeyer

Pamela Ciszewski

Michael Deixler

Justine Juson

cindy rothberg

Beata Lewis

Linda Mahaffey

Chris Talmage

David Rogoff

Lucy's Cure

platform

Platform is iOS

Android

Adyen Google Pay Development Audience

$opt_dummy_attribute

English only

Deprecate Stripe Legacy

dyn_template_ids

Adyen V6 Bene Transfer & MyMoney Campaign Organizers - test01

Bene transfer V6 and AdyenV6MyMoney Campaign Organizers - production

OneTrust next-app audience

fundCountryCode

NextDoor Share Option Users

Fundraisers with Reactions feature capability

fundCurrencyCode

US + Non-charity COs Only

locale

fund country is US and user language is English

personId

comms-internal-person-ids

Enhanced Story Experience Users

Suggested Goal Experience Users

user language is English and fund country: US, AU, DK, FI, IE, NO, SE, CA, GB; 

Poster share - new funds eligible (newest 9/18)

Streaming widgets beta user

paymentProcessor

3DS payment method

user language is English and fundCountry: US, AU, DK, FI, IE, NO, SE, CA, GB; 

GoFundMe Employees

ipAddress

Mark Rieth IP Address

Version 9.2.0 and above

Fund is in English speaking country

desktop

Android v12.11.0 and above

Platform is Android

paymentMethodType

checkoutType

Payment method type group to be vaulted on success

admin pr kit prod

EUR Donation Upsell

Share Text generation Skip Fundraiser

(prod) new funds eligible for amp12 (UGC gallery)

fintrac_cad_idv_form_v2 audience

paymentProcessorAccountId

fallback mode accounts

proCampaignId

p2p legacy startfundraising page

AMP24 New Funds Only PROD (DO NOT MODIFY)

countryCode

charityId

UKCharities

Federated Search Internal Testing

route.pathname community

US Donation Upsell audience 

Auto Thanks Feature Audience

Supporter Comments Eligible Funds

International Only

fundId

braze fundraiser group 

Payment Identity Transfers ATO Risk Check (Targeted) - Production

Fundraiser Saved Payment Method Rate Limit Bypass (Production)

leaderboard-partner-id-audience-givepanel

Version 9.2.1 and above

AUD Donation Upsell audience

fundraiserCountryCode is US/EN

Active Fundraiser - Smart Default Cadence

DAF Internal

Vault on success card payment method

Platform is iOS v11.0.0 and above

Desktop users

Person ids

United States (US) users

allow yuno fundraisers for test

Mexico country code

Posters INTL

NPO Profile Opted-In

iOS at or above 12.4.0

non-US recurring donors

Canada Campaign Owner Group

Fundraiser Without Meta Link

Scheduler payment tester gorup

charityCommunityId

Charities allow to be claimed unclaimed (PRD)

Canada (CA) users

currencyCode

UC Tipping v20250115 International

pymk_production_xplr_fe_team

Android at or above 12.2.0

Profile photo entry point audience

smart goals (fundraiser/manage) on test01

Activity Tracking v1 Beta Testing

writePath

Stream Notification

start gfm intl allowed locales

Platform is iOS v11.2.0 and above

unclaimed charities

prod_ach_audience

AI Chatbot Audience

amp13 only new funds (prod) (anyword auto)

UC Flow Enabled (Prod)

Payment Identity Beneficiary Verification - Production

shared notification bell audience

Custom users

ach frontend audience

Android v11.0.0 and above

Users Receiving Payments Paused Notifications

smart goals test01

Manage Coach - US English Organizers Only + new funds only

Team EGG - IP Address list

Fundraiser Without Instagram Deep Link

Native 11.4.0 and above

UC Tipping v20250107

Users Receiving Braze KYC Validation Failed

Native 11.3.0 and above

Influencer - Prod

US fundraisers and US users

ai_title_page

anyword

openai

control

manual_entry

userEmail

template_id

userId

fundUrl

isCharityCo

email

appVersion

shouldBucketIntoExperiment

partnerId

donationCadence

isActiveFundraiser

isPartner

isMobile

npoProfileOptIn

fundIsLinkedWithMeta

hasSessionDonation

isCampaignOwner

fundHasInstagramDeepLink

Native 11.4.0 and higher

New funds eligible - Video Sharing (PROD)

GB Donation Upsell audience 

Auto Thanks V3 Rollout Audience

Thank you V3 testing whitelist

isRecurringFriendly

Is Recurring Friendly

Excluded funds - Video Sharing

Logged In Users

CH Donation Upsell audience

Android v10.6.0 and above

userCurrencyCode

Localized Currency

v11.5.0 and above

testAudience

pathname

Survicate

appVersion is at or above 12.8.0

Non-charity fund

isChallengeFundraiser

challenge-fundraisers

Payment Identity Launch Verification - Production

New funds eligible - Posters v2

CAD Donation Upsell Audience

Braze Email Tester

NPO Profile Opted-Out

iOS App Version

hasKnownDonors

PYMK has donors

iOS v12.3.0 and above

Lucy's Cure

Still $161,027 to go. Help us build momentum.